Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C46H54N4O10 |
Molecular Weight | 822.9418 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 10 / 10 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12O[C@@]1(CC)CN3C[C@]2([H])C[C@@](C(=O)OC)(C4=C(CC3)C5=CC=CC=C5N4)C6=C(OC)C=C7N(C=O)[C@]8([H])[C@]9(CCN%10CC=C[C@@](CC)([C@@H](OC(C)=O)[C@]8(O)C(=O)OC)[C@@]9%10[H])C7=C6
InChI
InChIKey=GLDSBTCHEGZWCV-NVDFJPPOSA-N
InChI=1S/C46H54N4O10/c1-7-42-15-11-17-49-19-16-44(37(42)49)30-20-31(34(56-4)21-33(30)50(25-51)38(44)46(55,41(54)58-6)39(42)59-26(3)52)45(40(53)57-5)22-27-23-48(24-43(8-2)36(27)60-43)18-14-29-28-12-9-10-13-32(28)47-35(29)45/h9-13,15,20-21,25,27,36-39,47,55H,7-8,14,16-19,22-24H2,1-6H3/t27-,36+,37-,38+,39+,42+,43-,44+,45-,46-/m0/s1
Vinformide (also known as N-formylleurosine), an N-formyl analog of leurosine possesses antineoplastic activity. This drug was studied for the treatment of lymphoma, leukemia and Hodkin’s disease. However, studies were discontinued, because vinformide exerted an acute cardiotoxic side effect.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/539376
Six patients received one to three 5-day courses of formyl leurosine (FLR; VINFORMIDE). The total dose of FLR administered ranged from 15 to 131 mg (mean 83 mg).
Route of Administration:
Intravenous
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C274
Created by
admin on Fri Dec 15 15:55:01 GMT 2023 , Edited by admin on Fri Dec 15 15:55:01 GMT 2023
|
||
|
NCI_THESAURUS |
C932
Created by
admin on Fri Dec 15 15:55:01 GMT 2023 , Edited by admin on Fri Dec 15 15:55:01 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
I4U9NZS9T5
Created by
admin on Fri Dec 15 15:55:01 GMT 2023 , Edited by admin on Fri Dec 15 15:55:01 GMT 2023
|
PRIMARY | |||
|
4354
Created by
admin on Fri Dec 15 15:55:01 GMT 2023 , Edited by admin on Fri Dec 15 15:55:01 GMT 2023
|
PRIMARY | |||
|
269419
Created by
admin on Fri Dec 15 15:55:01 GMT 2023 , Edited by admin on Fri Dec 15 15:55:01 GMT 2023
|
PRIMARY | |||
|
SUB00064MIG
Created by
admin on Fri Dec 15 15:55:01 GMT 2023 , Edited by admin on Fri Dec 15 15:55:01 GMT 2023
|
PRIMARY | |||
|
C152883
Created by
admin on Fri Dec 15 15:55:01 GMT 2023 , Edited by admin on Fri Dec 15 15:55:01 GMT 2023
|
PRIMARY | |||
|
DTXSID60968854
Created by
admin on Fri Dec 15 15:55:01 GMT 2023 , Edited by admin on Fri Dec 15 15:55:01 GMT 2023
|
PRIMARY | |||
|
76972843
Created by
admin on Fri Dec 15 15:55:01 GMT 2023 , Edited by admin on Fri Dec 15 15:55:01 GMT 2023
|
PRIMARY | |||
|
54022-49-0
Created by
admin on Fri Dec 15 15:55:01 GMT 2023 , Edited by admin on Fri Dec 15 15:55:01 GMT 2023
|
PRIMARY | |||
|
CHEMBL2103947
Created by
admin on Fri Dec 15 15:55:01 GMT 2023 , Edited by admin on Fri Dec 15 15:55:01 GMT 2023
|
PRIMARY | |||
|
100000079111
Created by
admin on Fri Dec 15 15:55:01 GMT 2023 , Edited by admin on Fri Dec 15 15:55:01 GMT 2023
|
PRIMARY |
ACTIVE MOIETY